PE-22-28 vs Dihexa
Side-by-side comparison of PE-22-28 and Dihexa: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
PE-22-28
Dihexa
PE-22-28
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an…
Lowest listed price: $54.99 across 1 listing
Full PE-22-28 profileDihexa
Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models…
Lowest listed price: $79.99 across 3 listings
Full Dihexa profileSide-by-side comparison
| Attribute | PE-22-28 | Dihexa |
|---|---|---|
| Category | Nootropics | Nootropics |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation.… | Dihexa is a small-molecule analog derived from angiotensin IV (AngIV). It retains the Tyr-Ile core of Nle1-AngIV, with an N-terminal hexanoic acid cap and a C-terminal 6-aminohexanoic amide that give it metabolic stability and blood-brain-barrier penetration.… |
| Half-Life | Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. | Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. |
| Typical Dose Range | 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg). | 5 to 40 mg oral per day (anecdotal range; no established human dose) |
| Dosing Frequency | Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule). | Once daily (oral), typically in the morning |
| Administration | — | Oral, Intranasal, Subcutaneous |
| Side Effects | No human side-effect data exist for PE-22-28 because it has never been tested in people. What can be said comes from rodent studies of PE-22-28, spadin and their analogs, plus general considerations for injected research peptides. In the preclinical work, the… | No controlled human safety data. Anecdotal user reports include headache, fatigue, irritability or anxiety, insomnia, and vivid dreams, usually at higher doses. The most serious concern is theoretical rather than reported: because dihexa acts on the HGF/c-Met… |
| Molecular Weight | 773.9 g/mol | 504.7 g/mol |
| Common Vial Sizes | — | 50mg, 100mg |
Price tracking
Price tracking
PE-22-28: potential benefits
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
Dihexa: potential benefits
- Synaptogenesis: formation of new dendritic spines and functional synapses (preclinical)
- Memory and spatial-learning support in rodent models
- Potential research application in Alzheimer's and other neurodegenerative disease models
- HGF/c-Met and PI3K/Akt-linked neuroplasticity (mechanism proposed; key paper retracted)
Frequently asked
What's the difference between PE-22-28 and Dihexa?
PE-22-28 is a nootropics that pe-22-28 is a synthetic 7-amino-acid peptide (sequence gvswglr) and a shortened analog of spadin. its proposed mechanism is inhibition of the trek-1 (twik-related k+) channel, a…. Dihexa is a nootropics that dihexa is a small-molecule analog derived from angiotensin iv (angiv). it retains the tyr-ile core of nle1-angiv, with an n-terminal hexanoic acid cap and a c-terminal…. The two differ in mechanism, half-life (Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. vs Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.), and typical dose range.
Which has the longer half-life, PE-22-28 or Dihexa?
PE-22-28 has a half-life of Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].. Dihexa has a half-life of Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, PE-22-28 or Dihexa?
Lowest listed price on BodyHackGuide: PE-22-28 from $54.99, Dihexa from $79.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack PE-22-28 and Dihexa?
Stacking depends on mechanism overlap, safety profile, and goals. PE-22-28 and Dihexa should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy PE-22-28 or Dihexa
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.